---
schema_version: "secwatch.filing_event.v1"
accession: "0001846253-24-000032"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:03:29.592291+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OmniAb Q1 2024 revenue drops to $3.8M; net loss widens to $19.0M

## Summary
- Revenue $3.8M vs $16.9M YoY; net loss $19.0M ($0.19/share) vs $6.1M ($0.06/share) loss.
- Cash and short-term investments $69.0M; expects 2024 cash use similar to 2023 excluding $35M milestone.
- Signed three new license agreements; 80 active partners, 327 active programs, 31 in clinic.
- Pipeline: batoclimab MG Phase 3 topline H2 2024; IMVT-1402 plans 4-5 registrational programs.
- Guidance: 2024 operating expense flat vs 2023; cash use substantially lower in 2025.

## SEC filing metadata
- accession: 0001846253-24-000032
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000184625324000032/0001846253-24-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000184625324000032/oabi-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001846253-24-000032
- JSON: https://secwatch.observer/filing/0001846253-24-000032.json
- Plain text: https://secwatch.observer/filing/0001846253-24-000032.txt

## Key facts
- Earnings Releases
  OmniAb, Inc. reported the three months ended March 31, 2024 results: revenue $3.8 million, net income $19.0 million net loss, EPS $0.19 per share loss.
  - Period: the three months ended March 31, 2024
  - Revenue: $3.8 million
  - Net income: $19.0 million net loss
  - EPS: $0.19 per share loss
  - Result: reported results
  source text: to continued progress by our partners and expansion of our technology as the year progresses.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $3.8 million, compared with $16.9 million for the same period in 2023, with the decrease primarily due to the recognition in the 2023 period of a $10 million milestone related to the first
  evidence_url: https://www.sec.gov/Archives/edgar/data/1846253/000184625324000032/0001846253-24-000032-index.htm
- Earnings Releases
  OmniAb, Inc. reported the first quarter of 2024 results: revenue $3.8 million, net income $19.0 million net loss, EPS $0.19 per share loss.
  - Period: the first quarter of 2024
  - Revenue: $3.8 million
  - Net income: $19.0 million net loss
  - EPS: $0.19 per share loss
  - Result: reported results
  source text: to continued progress by our partners and expansion of our technology as the year progresses.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $3.8 million, compared with $16.9 million for the same period in 2023, with the decrease primarily due to the recognition in the 2023 period of a $10 million milestone related to the first
  evidence_url: https://www.sec.gov/Archives/edgar/data/1846253/000184625324000032/0001846253-24-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.